Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.35 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510380 | 0.91 | ACSS2 (0.37) | RAB9AEGLN2ACSS2MAP4K4LCK | |
| SCHEMBL15233045 | 0.83 | KDM4E (0.47) | RAB9ALCKMAPTEGFRMAPK1 | |
| SCHEMBL6513671 | 0.82 | ATR (0.36) | RAB9AEGLN2LEF1ACSS2MAP4K4 | |
| SCHEMBL5561204 | 0.82 | RHEB (0.41) | RAB9ALEF1LCKMAPTEGFR | |
| SCHEMBL14879026 | 0.81 | MAPT (0.37) | RAB9AMAPTEGFRMAPK1TP53 | |
| SCHEMBL6515389 | 0.79 | ACSS2 (0.35) | RAB9AEGLN2LEF1ACSS2MAP4K4 | |
| SCHEMBL14879048 | 0.78 | LCK (0.46) | RAB9ALCKMAPTEGFRMAPK1 | |
| SCHEMBL15233336 | 0.77 | ACSS2 (0.35) | RAB9AEGLN2ACSS2MAP4K4LCK | |
| SCHEMBL15233051 | 0.77 | ACSS2 (0.35) | RAB9AEGLN2ACSS2MAP4K4LCK | |
| SCHEMBL5560010 | 0.77 | MAPT (0.39) | RAB9ALEF1ACSS2LCKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1599474-B1 | Heterocyclic oligomeric compounds for DNA recognition | CALIFORNIA INST OF TECHN (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | DDB1, PCNA, DNA2 | RAB9A 4515/4885EGLN2 4349/4885LEF1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.